AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
2002 NOV 27 - (NewsRx.com & NewsRx.net) -- by Maria G. Essig, MS, ELS, senior medical writer - A vaccine containing a sonicated preparation of Aspergillus fumigatus protected mice against invasive pulmonary aspergillosis, according to a research group in California.
"Invasive pulmonary aspergillosis is an emerging devastating infection in the immunocompromised host that is treated with corticosteroids for neoplastic disease or for organ transplantation," explained James I. Ito and Joseph M. Lyons at the City of Hope National Medical Center in Duarte, California.
The investigators used corticosteroid-treated CF-1 mice to test the protective effects of prior infection and two different vaccine preparations against a potentially lethal dose of A. fumigatus. One vaccine was a sonicated preparation of A. fumigatus and the other was an A. fumigatus filtrate preparation. Vaccines were delivered either intranasally or subcutaneously (Vaccination of corticosteroid immunosuppressed mice against invasive pulmonary aspergillosis. Journal of Infectious Diseases, 2002;186(6):869-871).
All of the control mice died after A. fumigatus challenge. In contrast, none of the mice that received the sonicate vaccine subcutaneously died. Prior infection resulted in 12.5% mortality, intranasal sonicate preparation 29%, subcutaneous filtrate preparation 50%, and intranasal filtrate vaccine 75%.
...
Source: HighBeam Research, Vaccine protects against aspergillosis.